Research
Hormonal
DNA methylation levels in specific genes (e.g., PGC-1α, FTO, TCF7L2) are altered in patients with Type 2 Diabetes and obesity, serving as potential biomarkers for diagnosis and treatment response.
Blood tests measuring DNA methylation patterns (epigenetic biomarkers) may soon help predict who is at risk for diabetes or who will respond to specific drugs like metformin, allowing for more personalized prevention and treatment strategies.
GoodSupportsHIGH confidence
Notably, multiple epigenetic modifications are significantly correlated with metabolic disease-related gene function and expression and often occur early in diseases, thus exhibiting promising potential as clinical biomarkers for patients with metabolic diseases.
Why this rating
Supported by multiple cited studies (e.g., Dayeh et al., García-Calzón et al.) showing specific CpG site associations.
Source
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study
Yanlin Wu et al. · Signal Transduction and Targeted Therapy · 2023
DOI 10.1038/s41392-023-01333-7
narrative_reviewCited 426×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNA regulation, play a critical role in the initiation and progression of metabolic diseases such as type 2 diabetes, obesity, and NAFLD.Good
- Non-coding RNAs (miRNAs, lncRNAs, circRNAs) regulate gene expression in metabolic diseases and serve as diagnostic/prognostic biomarkers and potential therapeutic targets.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →